Aboul-Soud Mourad A M, El-Shemy Hany A, Aboul-Enein Khalid M, Mahmoud Ali M, Al-Abd Ahmed M, Lightfoot David A
Faculty of Agriculture Research Park (FARP) and Department of Biochemistry, Faculty of Agriculture, Cairo University, Giza 12613, Egypt; Chair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia.
Faculty of Agriculture Research Park (FARP) and Department of Biochemistry, Faculty of Agriculture, Cairo University, Giza 12613, Egypt.
Oncol Lett. 2016 Jan;11(1):642-648. doi: 10.3892/ol.2015.3916. Epub 2015 Nov 13.
Leukemias are a group of cancer types that originate from blood-forming tissues. In this disease, an abnormally large number of immature white blood cells is produced by the bone marrow. The relationship between treatments with plant-derived drugs and leukemia-associated immunophenotypes (LAIPs) of clinically isolated leukemia cells has yet to be established. The aim of the present study was to develop a preliminary clinical prognostic map for commonly expressed LAIPs in patients clinically diagnosed with leukemia, as well as to assess the potential involvement of LAIPs in the response rate to 10 natural products of plant origin. An increased expression of LAIPs, including CD4, CD14, CD33 and CD34, was considered a surrogate marker of the desired response of leukemia cells to treatment with plant-derived drugs. By contrast, the increased expression of the LAIPs, MPO and DR, was associated with poor prognostic outcomes following treatment with the plant-derived drugs. The results showed that 5 of the 10 plant-derived drugs tested induced the expression of several desirable LAIPs biomarkers. These findings clearly highlight the potential treatment efficacy of certain plant-derived drugs against leukemic cell types.
白血病是一类起源于造血组织的癌症。在这种疾病中，骨髓会产生数量异常多的未成熟白细胞。植物源药物治疗与临床分离的白血病细胞的白血病相关免疫表型（LAIPs）之间的关系尚未确立。本研究的目的是为临床诊断为白血病的患者中常见表达的LAIPs制定初步的临床预后图谱，并评估LAIPs对10种植物源天然产物反应率的潜在影响。LAIPs（包括CD4、CD14、CD33和CD34）表达增加被认为是白血病细胞对植物源药物治疗产生预期反应的替代标志物。相比之下，LAIPs、MPO和DR表达增加与植物源药物治疗后的不良预后结果相关。结果显示，所测试的10种植物源药物中有5种诱导了几种理想的LAIPs生物标志物的表达。这些发现清楚地突出了某些植物源药物对白血病细胞类型的潜在治疗效果。
